Editas Medicine, Inc. (EDIT)
Preborsa:
| Chiusura precedente | 18,23 |
| Aperto | 18,86 |
| Denaro | 18,00 x 1200 |
| Lettera | 18,46 x 1100 |
| Min-Max giorno | 17,62 - 19,83 |
| Intervallo di 52 settimane | 16,37 - 73,03 |
| Volume | |
| Media Volume | 1.537.827 |
| Capitalizzazione | 1,218B |
| Beta (5 anni mensile) | 1,91 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -3,23 |
| Prossima data utili | 23 feb 2022 - 28 feb 2022 |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 49,71 |
- GlobeNewswire
Editas Medicine Reports on Recent Progress and Outlook at J.P. Morgan Healthcare Conference
James C. Mullen James C. Mullen, Chairman, President, and Chief Executive Officer of Editas Medicine Anticipated 2022 milestones include initial clinical data for EDIT-301 in sickle cell disease by year-end, dosing of first TDT patient with EDIT-301, initiation of pediatric high-dose cohort for EDIT-101 in LCA10, and a clinical data update on EDIT-101 in the second half of 2022 Company announces new development candidates EDIT-103 for RHO-adRP and EDIT-202 multiplexed iNK cell therapy for solid
- GlobeNewswire
Editas Medicine to Present at the 40th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will present a company overview and update at the 40th Annual J.P. Morgan Healthcare Conference, held virtually, on Wednesday, January 12, 2022, at 10:30 a.m. ET A live webcast of the presentation will be available on the Investors section of the Editas Medicine website at www.editasmedicine.com. An archived replay will be available on the website fo
- GlobeNewswire
Dr. Jessica Hopfield Appointed to Berkeley Lights Board of Directors
Addition of Experienced Independent Director with Accomplished Business Record Underscores Berkeley Lights Board of Directors’ Commitment to Delivering Value for ShareholdersEMERYVILLE, Calif., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, today announced the appointment of Jessica Hopfield, Ph.D. to the Berkeley Lights’ Board of Directors as an independent director, effective December 15, 2021. "Dr. Hopfield is a respected and accomplis
